Click here to


Are you sure ?

Yes, do it No, cancel

Clinical Implementation of FDA Approved Radiopharmaceutical Lu-177

S George1*, J George1 , V Mishra1 , M Chuong1 , A Gutierrez1 , Miami Cancer Institute, Miami, FL


(Sunday, 7/14/2019)  

Room: ePoster Forums

Purpose: Illustrate the method that we used at MCI to implement the new FDA approved radio pharmaceutical Lu-177 for neuroendocrine Tumors. This presentation is specifically highlighting the coordination efforts to consolidate all the aspects of Lu-177 therapy in the Radiation Oncology Department (including the injection of Amino Acids and peptide receptors as well as the Radio pharmaceutical).

Methods: Work- flow development, multiple meetings, implementation, Calibration and coordination with Nuclear Medicine, Radio-active Assay, Pharmacy. Quality Assurance and Safety along with licensing issues related to this process.

Results: Successful implementation of Lu-177 treatment at the Radiation Oncology Department of Miami Cancer Institute.

Conclusion: We were able to treat the Lu-177 patient at Radiation Oncology Department at MCI.


Not Applicable / None Entered.


IM/TH- Radiopharmaceutical therapy: Safety, QA, and radiation protection

Contact Email